New drug combo tested to shrink aggressive breast cancer before surgery
NCT ID NCT01796197
Summary
This study tested a combination of three drugs—paclitaxel, trastuzumab, and pertuzumab—given to patients before surgery for a fast-growing type of breast cancer called inflammatory breast cancer. The main goals were to see if the treatment could completely eliminate the cancer from the breast and lymph nodes by the time of surgery, and to lower the chance of the cancer coming back later. Researchers also collected tissue samples to try to learn which patients might respond best to this type of treatment in the future.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Brigham and Women's Hospital
Boston, Massachusetts, 02215, United States
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
University of Michigan
Ann Arbor, Michigan, 48109, United States
Conditions
Explore the condition pages connected to this study.